Company Overview
About Neurona Therapeutics
Neurona Therapeutics is a clinical-stage biotherapeutics company founded in 2013 and headquartered in San Francisco, California, that develops regenerative neural cell therapies for chronic neurological disorders. The company generates specific neuronal and glial cell types from human induced pluripotent stem cells (iPSCs) for transplantation into the nervous system, with the goal of repairing dysfunctional neural circuits that underlie conditions such as epilepsy, chronic pain, and other neurological diseases.
Business Model & Competitive Advantage
Neurona's lead program, NRTX-1001, consists of human interneuron progenitor cells derived from iPSCs that, once transplanted into the brain, mature into inhibitory interneurons — a cell type that is reduced or dysfunctional in drug-resistant focal epilepsy. In Phase 1/2 clinical trials, multiple patients treated with NRTX-1001 have shown dramatic reductions in seizure frequency, with some achieving complete seizure freedom — an outcome that is extremely rare in drug-resistant epilepsy. These early results have generated significant clinical excitement, as approximately one-third of epilepsy patients do not respond adequately to available medications.
Competitive Landscape 2025–2026
Neurona Therapeutics has raised over $115 million in total funding, including a $60 million Series C in 2024. Key investors include ARCH Venture Partners, F-Prime Capital, and GV. The company is also advancing NRTX-2001 for chronic pain and exploring additional neurological indications where interneuron transplantation may restore circuit balance. Neurona's approach is part of a broader emerging field of cell therapy for non-oncology indications, applying the manufacturing and cell engineering expertise developed in cancer cell therapy to neurological diseases.
Key Differentiators
Emerging Innovator
Neurona Therapeutics is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Circle Pharma
Circle Pharma is a clinical-stage biopharmaceutical company founded in 2016 by Matthew Jacobson, Siegfried Bhagwati, and Grace Aldrovandi, headquartered in San Francisco, California. The company is de
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
Tempus
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder o
Karius
Karius is a Redwood City, CA-based life sciences company founded in 2014 that developed the Karius Test — a single blood draw that uses next-generation sequencing and AI to detect over 1,000 pathogens
Saluda Medical
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US oper
Compare Neurona Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Neurona Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Neurona Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Neurona Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →